iRadimed

IRMD

Market cap $934M

iRadimed (IRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts.

IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Iradimed (IRMD) Q2 Revenue Jumps 14%

IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.

iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.